Summit Therapeutics (SMMT) is down -6.9%, or -$1.86 to $25.12.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Akeso says ivonescimab met overall survival endpoint in final anlysis
- Summit Therapeutics price target raised to $50 from $44 at H.C. Wainwright
- Summit Therapeutics’ Ivonescimab: A Promising Competitor to Keytruda with Increased Approval Probability and Price Target
- Summit Therapeutics put volume heavy and directionally bearish
- Piper starts Summit Therapeutics with Neutral on high expectations